All companies › QNRX

QNRX · Quoin Pharmaceuticals, Ltd.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys4
Open-market sells0
Total purchased$279,966
Unique insiders buying4
Most senior buyerCEO
Avg price paid$4.88
Research cases0
Last filing2026-08-31

Average price paid is weighted by shares, so a large purchase counts for more than a small one. It is what insiders reported paying, not a target or a fair value.

Insider flow: Buying only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-08-31 — Carter Denise P. · bought 20,490 @ $4.88 2026-08-31 — Myers Michael · bought 20,490 @ $4.88 2026-08-31 — Lawlor Sally Bridget · bought 10,244 @ $4.88 2026-08-31 — Culverwell Anthony James · bought 6,146 @ $4.88
2026-08-312026-08-31

Insider cost basis

Share-weighted average price across 4 reported purchases, with the full range of prices paid. Purchases only — averaging a sale into an "insider cost" would describe a price nobody paid.

$4.88 $4.88
$4.88 weighted average insider purchase price

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Carter Denise P. Chief Operating Officer
Myers Michael Chief Executive Officer
Lawlor Sally Bridget Chief Financial Officer
Culverwell Anthony James Director
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $QNRX is the reading of them — and for this company, that is what the list below says it is, no more.

  • Insider cost basisShare-weighted average price paid across the 4 reported purchases, with the full range, against the current price.
  • Insider participationWho bought, how often, and how the buying is distributed across the people filing — one person repeating is not several agreeing.
  • Transaction timelineThe [{'transaction_date': '2026-08-31', 'insider_name': 'Carter Denise P.', 'insider_title': 'Chief Operating Officer', 'transaction_type': 'Open-market buy', 'shares': 20490.0, 'price': 4.88, 'value': 99991.2, 'is_buy': True}, {'transaction_date': '2026-08-31', 'insider_name': 'Myers Michael', 'insider_title': 'Chief Executive Officer', 'transaction_type': 'Open-market buy', 'shares': 20490.0, 'price': 4.88, 'value': 99991.2, 'is_buy': True}, {'transaction_date': '2026-08-31', 'insider_name': 'Lawlor Sally Bridget', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market buy', 'shares': 10244.0, 'price': 4.88, 'value': 49990.72, 'is_buy': True}, {'transaction_date': '2026-08-31', 'insider_name': 'Culverwell Anthony James', 'insider_title': 'Director', 'transaction_type': 'Open-market buy', 'shares': 6146.0, 'price': 4.88, 'value': 29992.48, 'is_buy': True}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for QNRX today: no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.